(Total Views: 731)
Posted On: 03/08/2021 11:18:21 PM
Post# of 148928
Re: Riztheinvestor #82165
Had to do this...too good to not have grabbed the below post from the 'other' place (ty jimmy667). Ritz - I'm with you, Nader is relentless and a bit off beat, most people who defy odds have to be that way. I know if I put 10+ years in my life dedicated to a single thing, I sure as heck won't give up easy..I trust the bulldog to win the fight. See everyone in a few months.
=======================================
The results of CD12 added $5 billion (at a minimum) to the value of CytoDyn. It has just not shown up in the market cap....yet.
Let this sink in....all the BP drugs and trials have failed. Only
Dexamethasone has shown reliable utility for Covid....it comes with a high price...organ failure.
CytoDyn drug did not fail...it showed remarkable signal...the trial was flawed in several ways as it was designed in the early days of the pandemic. It needed a larger N of critical and a different design.
Most all the other BP trials ended in terminal failure. Most drugs need to have several Phase 3s on the way to approval.
Most of other drugs are not getting that chance.
CytoDyn has a fairly quick and sure path to approval. I can not stress enough the immense value of the knowledge gained in these two prior trials in designing this likely last trial for acute Covid. Then there is the long haulers trial...again Leronlimab is ahead here as well as one of the only drugs in the race.
If this were a scam there would not be a cacophony of shrill voices calling it such.
This is a disruptive drug for a possible multitude of indications. The company has a eccentric CEO .....Steve Jobs was fired at Apple. Everyone thought Elon Musk was an dreamer in the early years and that his vision would never succeed.
Say what you will about Nader but the man has vision.
How many metals did Edison test before he found tungsten?
The short sighted see CD12 as a failure. It is but one step along the way.
Nearly all Biotechs face stumbling blocks. Where so many warn of danger is the time and place of opportunity...on the path to success.
=======================================
The results of CD12 added $5 billion (at a minimum) to the value of CytoDyn. It has just not shown up in the market cap....yet.
Let this sink in....all the BP drugs and trials have failed. Only
Dexamethasone has shown reliable utility for Covid....it comes with a high price...organ failure.
CytoDyn drug did not fail...it showed remarkable signal...the trial was flawed in several ways as it was designed in the early days of the pandemic. It needed a larger N of critical and a different design.
Most all the other BP trials ended in terminal failure. Most drugs need to have several Phase 3s on the way to approval.
Most of other drugs are not getting that chance.
CytoDyn has a fairly quick and sure path to approval. I can not stress enough the immense value of the knowledge gained in these two prior trials in designing this likely last trial for acute Covid. Then there is the long haulers trial...again Leronlimab is ahead here as well as one of the only drugs in the race.
If this were a scam there would not be a cacophony of shrill voices calling it such.
This is a disruptive drug for a possible multitude of indications. The company has a eccentric CEO .....Steve Jobs was fired at Apple. Everyone thought Elon Musk was an dreamer in the early years and that his vision would never succeed.
Say what you will about Nader but the man has vision.
How many metals did Edison test before he found tungsten?
The short sighted see CD12 as a failure. It is but one step along the way.
Nearly all Biotechs face stumbling blocks. Where so many warn of danger is the time and place of opportunity...on the path to success.
(23)
(1)Scroll down for more posts ▼
